Comparative Pharmacology
Head-to-head clinical analysis: KIMIDESS versus NYLIA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KIMIDESS versus NYLIA 7 7 7.
KIMIDESS vs NYLIA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
5 mg orally once daily, with or without food.
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive